Clinical Trial Update: A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the activity and safety of combining cabozantinib with temozolomide in lung and gastroenteropancreatic neuroendocrine tumors t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Lung Neuroendocrine Tumor

Drugs mentioned

• Temodar (Temozolomide)
• cabozantinib (cabozantinib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor | Phase 2 | Status: RECRUITING